NDA 019715 · Mylan Spclt Viatris
Dipentum
Olsalazine Sodium · Oral
NovelPriority reviewLast checked: Nov 20, 2026Latest source record: Oct 14, 2026 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
1990
Jul 31, 1990
Approved uses
1
Original approval plus efficacy supplements
Registered trials
2
1 Phase 3, 0 recruiting
FAERS reports
197
146 serious, 11 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect May 15, 2026.
DIPENTUM is indicated for the maintenance of remission of ulcerative colitis in adult patients who are intolerant of sulfasalazine. DIPENTUM is an aminosalicylate indicated for the maintenance of remission of ulcerative colitis in adult patients who are intolerant of sulfasalazine. ( 1 )
Mechanism: Upon reaching the colon, colonic bacteria convert olsalazine into 5‑aminosalicylic acid (5-ASA or mesalazine). The mechanism of action of 5-ASA (mesalamine) is not fully understood, but appears to be a topical anti-inflammatory effect on colonic epithelial cells. Mucosal production of arachidonic acid metabolites, both through the cyclooxygenase pathways (i.e., prostanoids) and through the lipoxygenase pathways (i.e., leukotrienes and hydroxyeicosatetraenoic acids) is increased in patients with ulcerative colitis, and it is possible that mesalamine diminishes inflammation by blocking...
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Jul 31, 1990 Original approval · Type 1 - New Molecular Entity · priority review
1 products under this application
- DIPENTUM · OLSALAZINE SODIUM 250MG · CAPSULE, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Olsalazine" as an intervention, any sponsor and status, largest first.
- Randomized Placebo-Controlled Trial of Budesonide Multi-Matrix System (MMX®) 9 Milligrams (mg) in Participants With Ulcerative Colitis Currently on a 5-Aminosalicylic Acid (5-ASA)Pivotal-lookingCompleted
Bausch Health Americas, Inc.Industry
NCT01532648 · 510 participants · Start Jan 27, 2012 · Primary completion Oct 2, 2013
Drug: Budesonide MMX®; Placebo and 1 more · For: Ulcerative Colitis
Sites: Anaheim, California; Lakewood, California; San Diego, California · 114 sites in all
National Center for Research Resources (NCRR)NIH
NCT00004288 · 4 participants · Start May 1996
Drug: olsalazine · For: Ankylosing Spondylitis
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- colitis ulcerative19
- diarrhoea14
- drug ineffective12
- off label use11
- fatigue9
- pain8
- pain in extremity7
- pruritus7
- pyrexia7
- abdominal pain6
- anxiety6
- arthralgia6
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2004 | 14 |
| 2005 | 18 |
| 2006 | 11 |
| 2007 | 8 |
| 2008 | 11 |
| 2009 | 18 |
| 2010 | 14 |
| 2011 | 18 |
| 2012 | 9 |
| 2013 | 10 |
| 2014 | 9 |
| 2015 | 9 |
| 2016 | 7 |
| 2017 | 4 |
| 2018 | 4 |
| 2019 | 5 |
| 2020 | 6 |
| 2021 | 10 |
| 2022 | 3 |
| 2023 | 3 |
| 2024 | 3 |
| 2025 | 2 |
| 2026 | 1 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Dipentum (Olsalazine Sodium)
2024 spending
$2.9M
Beneficiaries
194
1,345 claims
Per beneficiary
$14,808
$14.55 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $3,782,856 |
| 2021 | $3,090,782 |
| 2022 | $3,016,255 |
| 2023 | $2,854,712 |
| 2024 | $2,872,707 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Evolution of olsalazine.
Truelove SC · Scand J Gastroenterol Suppl 1988 · Biography, Clinical Trial
- Aminosalicylates for induction of remission or response in Crohn's disease.
Lim WC, Wang Y, MacDonald JK, et al. · Cochrane Database Syst Rev 2016 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Olsalazine in active ulcerative colitis.
Selby WS, Barr GD, Ireland A, et al. · Br Med J (Clin Res Ed) 1985 · Clinical Trial, Randomized Controlled Trial
- Oral 5-aminosalicylic acid preparations in treatment of inflammatory bowel disease. An update.
Martin F · Dig Dis Sci 1987 · Clinical Trial, Review
- Optimum dose of olsalazine for maintaining remission in ulcerative colitis.
Travis SP, Tysk C, de Silva HJ, et al. · Gut 1994 · Clinical Trial, Comparative Study
- Olsalazine in patients intolerant of sulphasalazine.
Ireland A, Jewell DP · Scand J Gastroenterol 1987 · Clinical Trial
Sponsor: Mylan Spclt Viatris
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.